secwatch.observer — SEC 8-K summary
======================================

Issuer:     Actinium Pharmaceuticals, Inc. (ATNM)
CIK:        0001388320
Form:       8-K
Filed at:   2026-06-18T21:00:24+00:00
Accession:  0001213900-26-070193
Event type: other_material
Sentiment:  negative
Materiality: 0.65
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Actinium submits NYSE American compliance plan after equity deficiency notice
-----------------------------------------------------------------------------

- Received NYSE American deficiency notice on May 27, 2026, for Section 1003(a)(ii): equity below required $4M.
- Submitted compliance plan on June 18, 2026, outlining intended actions to restore listing standards.
- No specific plan details disclosed; exchange will review plan during continued trading.
- Company faces potential delisting if plan not accepted or compliance not achieved within extension period.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1388320/000121390026070193/0001213900-26-070193-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1388320/000121390026070193/ea0295259-8k_actinium.htm
  HTML page:      https://secwatch.observer/filing/0001213900-26-070193

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer